Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) CEO Clarissa Sowemimo-Coker speaks to Proactive after the pharmaceutical group confirmed that she has now taken on the role on a permanent basis, having been appointed on an interim basis in December 2022.
Sowemimo-Coker highlights the ongoing work on four drug development programs, including awaiting approval from MHRA for the lead program targeting chemotherapy induced peripheral neuropathy.